VISEN Pharmaceuticals (HKG:2561)
Hong Kong
· Delayed Price · Currency is HKD
25.20
0.00 (0.00%)
Apr 29, 2026, 4:08 PM HKT
VISEN Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Operating Revenue | 0.17 | - | - | - |
| Other Revenue | -0.03 | 2.78 | -1.67 | -2.3 |
| Revenue | 0.14 | 2.78 | -1.67 | -2.3 |
| Revenue Growth (YoY) | -95.10% | - | - | - |
| Cost of Revenue | 0.15 | - | - | - |
| Gross Profit | -0.01 | 2.78 | -1.67 | -2.3 |
| Selling, General & Admin | 146.33 | 86.43 | 79.94 | 177.45 |
| Research & Development | 93.48 | 90.52 | 57.69 | 179.55 |
| Operating Expenses | 239.81 | 176.96 | 137.63 | 357 |
| Operating Income | -239.82 | -174.18 | -139.3 | -359.29 |
| Interest Expense | -1.1 | -0.16 | -0.32 | -0.62 |
| Interest & Investment Income | 11.78 | 6.77 | 11.15 | 5.57 |
| Currency Exchange Gain (Loss) | -13.64 | 2.69 | 4.71 | 79.78 |
| Other Non Operating Income (Expenses) | -10.64 | -17.37 | -16.28 | -14.3 |
| EBT Excluding Unusual Items | -253.42 | -182.24 | -140.05 | -288.86 |
| Gain (Loss) on Sale of Assets | - | - | -0.24 | -0.1 |
| Other Unusual Items | - | - | -109.28 | - |
| Pretax Income | -253.42 | -182.24 | -249.57 | -288.97 |
| Net Income | -253.42 | -182.24 | -249.57 | -288.97 |
| Net Income to Common | -253.42 | -182.24 | -249.57 | -288.97 |
| Shares Outstanding (Basic) | 104 | 94 | 94 | - |
| Shares Outstanding (Diluted) | 104 | 94 | 94 | - |
| Shares Change (YoY) | 10.71% | - | - | - |
| EPS (Basic) | -2.44 | -1.95 | -2.67 | - |
| EPS (Diluted) | -2.44 | -1.95 | -2.67 | - |
| Free Cash Flow | - | -140.98 | -271.83 | -248.03 |
| Free Cash Flow Per Share | - | -1.51 | -2.90 | - |
| Gross Margin | -7.35% | 100.00% | - | - |
| Operating Margin | -176338.97% | -6272.16% | - | - |
| Profit Margin | -186339.71% | -6562.55% | - | - |
| Free Cash Flow Margin | - | -5076.52% | - | - |
| EBITDA | -239.11 | -173.46 | -137.79 | -357.55 |
| D&A For EBITDA | 0.72 | 0.72 | 1.51 | 1.74 |
| EBIT | -239.82 | -174.18 | -139.3 | -359.29 |
Source: S&P Capital IQ. Standard template.
Financial Sources.